Sign In
Home
About Us
Benefits
Pricing
Krixos GmbH
Contact Us
Subscribe now
Breaking Cancer News A-Z
Health/Pharma Companies
Drugs, Treatments, Trials
Hot Topics
Clinical Trials - Latest News
Other Illnesses & Conditions
Latest Healthcare News
My Settings
Client Requests
Advanced Search
My Viewed Articles
All Cancer News
Acute Lymphoblastic Leukemia
Acute myeloid leukemia
Adenocarcinoma
Adenoid Cystic Carcinoma
Adrenocortical Carcinoma
Anal Cancer
Anaplastic Astrocytoma
Angiosarcoma
Astrocytoma
Basal-Cell Carcinoma
Bladder Cancer
Brain Cancer
Breast Cancer
Cancer Cachexia
Carcinoma
Cervical Cancer
Childhood Cancer
Cholangiocarcinoma
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Adenocarcinoma
Colorectal Cancer
Craniopharyngioma
Endometrial Cancer
Ependymoma
Esophageal Cancer
Ewing's Sarcoma
Gallbladder Cancer
Germ Cell Tumors
Glioblastoma
Glioma
Hairy Cell Leukemia
Hepatocellular Carcinoma
Hodgkin Lymphoma
Kaposi's Sarcoma
Kidney & Renal Cancer
Laryngeal Cancer
Leukemia
Liver Cancer
Lung Adenocarcinoma
Lung Cancer
Lymphoma
Mantle Cell Lymphoma
MCRPC
Medulloblastoma
Melanoma
Meningioma
Mesothelioma
Metastatic Colon Cancer
Mouth Cancer
Multiple Myeloma
Myelodysplastic Syndrome
Myelofibrosis
Nasopharyngeal Carcinoma
Neuroblastoma
NMIBC
Non-Hodgkin Lymphoma
NSCLC
Oral Cancer
Oropharyngeal Cancer
Osteosarcoma
Ovarian Cancer
Pancreatic Adenocarcinoma
Pancreatic Cancer
Pancreatic Neuroendocrine Tumors
Penile Cancer
Pheochromocytoma
Prostate Cancer
Retinoblastoma
Rhabdomyosarcoma
Sarcoma
Sarcopenia
Skin Cancer
Small Cell Lung Cancer
Squamous Cell Carcinoma
Stomach (Gastric) Cancer
Synovial Sarcoma
Testicular Cancer
Thymic Carcinoma
Thymoma
Thyroid Cancer
Tongue Cancer
Uterine Cancer
Vulvar Cancer
You need to login...
Enter your email:
Enter your password:
If you are not registered...
Subscribe to Cancer Stat:
Sign Up Now:
Your email:
or call us on: +44 (0)20 7769 6707
or email:
apus@templetonapus.com
Most viewed
1.
Ionis and UCSD take an antisense approach to fighting treatment-resistant multiple myeloma
2.
TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009, a Phase 1B Dual Angiogenic Bispecific Antibody Targeting DLL4/VEGF
3.
COVID Vaccines: Ask The Experts
4.
A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated
5.
2021 Biotech IPOs Get Off to a Roaring Start
6.
Merck, Bayer win FDA approval for heart failure drug
7.
MyID Launches Partnership with Merck
8.
Robert Embree and Jason Allchin Team Up to Start EmeritusDX
9.
NEUVOGEN Announces Participation at B. Riley Virtual Oncology Investor Conference
10.
We Dare You Not To Smile as Survivors Ring Bells Celebrating End of Cancer Journeys in Uplifting TikTok Videos
Last updated at 11:05 GMT
Hot News Makers
Health/Pharma Companies
Qiagen
61265.82
ProLung
23406.93
Penumbra Inc
14865.21
ImmunoLogik
12917.67
Capsugel
12643.28
Pneumagen
11069.62
Imugene
10415.03
Zbiotics
9878.87
Yangtze River Pharma
9188.43
Sino Biopharmaceutical
8039.82
Last updated at 10:10 GMT